236 related articles for article (PubMed ID: 24640967)
61. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Jabbour EJ; Kantarjian H; Eliasson L; Cornelison AM; Marin D
Am J Hematol; 2012 Jul; 87(7):687-91. PubMed ID: 22473898
[TBL] [Abstract][Full Text] [Related]
62. Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.
Kim Y; Go TH; Jang J; Lee JB; Lim ST; Shim KY; Lee JI; Kong JH
Korean J Intern Med; 2021 Nov; 36(6):1450-1458. PubMed ID: 34742178
[TBL] [Abstract][Full Text] [Related]
63. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS
Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021
[TBL] [Abstract][Full Text] [Related]
64. Prevalence of therapeutic drug monitoring and adherence to imatinib in chronic myeloid leukemia in Japan.
Kawabe K; Nakayama T; Fukuoka N; Sakamoto Y; Goto H; Suzuki T; Koike H; Sahashi Y; Ooba N
Int J Clin Pharmacol Ther; 2022 Nov; 60(11):469-476. PubMed ID: 35924643
[TBL] [Abstract][Full Text] [Related]
65. Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia.
Del Rosario García B; Viña Romero MM; González Rosa V; Alarcón Payer C; Oliva Oliva L; Merino Alonso FJ; Nazco Casariego GJ; Gutiérrez Nicolás F
J Oncol Pharm Pract; 2024 Jul; 30(5):902-906. PubMed ID: 37748859
[TBL] [Abstract][Full Text] [Related]
66. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
Shen C; Zhao B; Liu L; Shih YT
Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
[TBL] [Abstract][Full Text] [Related]
67. Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors.
Rychter A; Jerzmanowski P; Hołub A; Specht-Szwoch Z; Kalinowska V; Tęgowska U; Seferyńska I; Kołkowska-Leśniak A; Lech-Marańda E; Góra-Tybor J
Med Oncol; 2017 Jun; 34(6):104. PubMed ID: 28444623
[TBL] [Abstract][Full Text] [Related]
68. Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia.
Clark SE; Marcum ZA; Radich JP; Bansal A
J Oncol Pharm Pract; 2021 Dec; 27(8):1842-1852. PubMed ID: 33175653
[TBL] [Abstract][Full Text] [Related]
69. Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study.
Leader A; Gafter-Gvili A; Benyamini N; Dreyer J; Calvarysky B; Amitai A; Yarchovsky-Dolberg O; Sharf G; Tousset E; Caspi O; Ellis M; Levi I; Raanani P; De Geest S
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):e351-e362. PubMed ID: 30122203
[TBL] [Abstract][Full Text] [Related]
70. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
[TBL] [Abstract][Full Text] [Related]
71. Two-Way Clinical Messaging in a CML Specialty Pharmacy Service Model.
Sawicki C; Friend KE; Patel R; Polinski JM; Singh S
J Manag Care Spec Pharm; 2019 Nov; 25(11):1290-1296. PubMed ID: 31663460
[TBL] [Abstract][Full Text] [Related]
72. Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors.
Maeda Y; Okamoto A; Kawaguchi SI; Konishi A; Yamamoto K; Eguchi G; Kanai Y; Yamaguchi T
Acta Haematol; 2017; 138(3):140-142. PubMed ID: 28869927
[No Abstract] [Full Text] [Related]
73. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence.
Shallis RM; Wang R; Zeidan AM; Huntington SF; Neparidze N; Stempel JM; Mendez LM; Di M; Ma X; Podoltsev NA
Blood Adv; 2023 Jul; 7(13):3213-3224. PubMed ID: 36939371
[TBL] [Abstract][Full Text] [Related]
74. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.
McGarry LJ; Chen YJ; Divino V; Pokras S; Taylor CR; Munakata J; Nieset CC; Huang H; Jabbour E; Malone DC
Curr Med Res Opin; 2016; 32(2):289-99. PubMed ID: 26566171
[TBL] [Abstract][Full Text] [Related]
75. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial.
Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798
[TBL] [Abstract][Full Text] [Related]
76. Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study.
Iwamoto T; Monma F; Ohishi K; Umino A; Suzuki K; Oka K; Kawakami K; Sekine T; Okuda M; Katayama N
Ther Drug Monit; 2019 Oct; 41(5):575-581. PubMed ID: 31008998
[TBL] [Abstract][Full Text] [Related]
77. Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients.
Boons CCLM; Tromp VNMF; Neppelenbroek NJM; Timmers L; van Schoor NM; Swart EL; Hendrikse NH; Janssen JJWM; Hugtenburg JG
Acta Oncol; 2019 Jun; 58(6):891-896. PubMed ID: 30905234
[No Abstract] [Full Text] [Related]
78. [Progress of Researches on Prediction of Tyrosine Kinase Inhibitor Efficacy for Treatment of Chronic Myelocid Leukemia -Review].
Ding YH; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):249-254. PubMed ID: 28245411
[TBL] [Abstract][Full Text] [Related]
79. Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).
Philipp M; Schwaab J; Dietz CT; Hanfstein B; Kalmanti L; Munjal U; Mossner M; Nowak D; Seifarth W; Hofmann WK; Hochhaus A; Müller MC; Erben P
J Cancer Res Clin Oncol; 2014 Mar; 140(3):411-7. PubMed ID: 24390277
[TBL] [Abstract][Full Text] [Related]
80. CML patients in the molecular era - report of five years experience of diagnosis and treatment in a single center.
Voican I; Vladareanu AM; Bumbea H; Barsan L; Vasile D
J Med Life; 2013 Sep; 6(3):319-26. PubMed ID: 24146695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
